Rashid Syed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rashid Syed has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abbas A. Karim
John Sealy School of Medicine, University of Texas of Medical Branch (UTMB) , Galveston, TX 77555
1 shared publication - Amina El Ayadi
Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA
1 shared publication - Chris Hsu
John Sealy School of Medicine, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, USA
1 shared publication - Farhad Al Marzook
John Sealy School of Medicine
1 shared publication - George Golovko
Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, USA
1 shared publication - Gopal Kumar Yadav
Department of Diagnostic‐Radiology University of Texas Medical Branch Galveston Texas USA
1 shared publication
Latest Publications
- Open Access
- 15 April 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (7) , 2757-2762
Added value of restricted diffusion in acute pyelonephritis: Two cases with different clinical presentations
- 15 April 2026
- Published by Elsevier in Radiology Case Reports
- Vol. 21 (7) , 2757-2762
Open AccessAdded value of restricted diffusion in acute pyelonephritis: Two cases with different clinical presentations
- 23 January 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (3) , 706-717
Prescription Analysis of Antihistamines’ Use in Patients With Moderate to Severe Burns
Postburn pruritus (PBP) significantly affects patients, causing discomfort and hindering recovery. Antihistamines, which block H1 receptors, are commonly prescribed for PBP, yet large-scale studies on their usage patterns are limited. This study evaluates antihistamine prescription trends and provider practices for PBP across varying burn severities from moderate to severe burns (≥20% TBSA). A treatment-pathways analysis was performed using TriNetX, a global, federated, deidentified database. Patients with burns ≥ 20% TBSA from the past 20 years (2004-2024) who developed pruritus were identified and stratified into 4 cohorts: 20%-40%, 40%-60%, 60%-80%, and ≥ 80% TBSA. The analysis evaluated trends in antihistamine prescriptions, including the number of patients treated with antihistamines, types prescribed, and median times to treatment initiation, duration, and therapy switching. The total sample included 2754 patients (20%-40% TBSA, n = 1712; 40%-60%, n = 613; 60%-80%, n = 253; ≥80%, n = 176). Over 70% received antihistamines, with hydroxyzine as the most common first-line therapy, followed by diphenhydramine. Across all cohorts, the average of the median times for initiation, therapy duration, and time before switching was 16.75 days, 90.25 days, and 27.75 days, respectively. Significant variations in the timing of therapy initiation suggest a gap in consistent symptom management during critical recovery periods, potentially affecting patient comfort and overall outcomes. These findings underscore the importance of vigilant postburn assessment, stepwise escalation based on response, and complementary strategies to optimize PBP management. Frequent switching and prolonged durations suggest a need for more effective and tailored therapeutic approaches to improve recovery outcomes for patients with burn injuries.
- 23 January 2026
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
- Vol. 47 (3) , 706-717
Prescription Analysis of Antihistamines’ Use in Patients With Moderate to Severe Burns
Postburn pruritus (PBP) significantly affects patients, causing discomfort and hindering recovery. Antihistamines, which block H1 receptors, are commonly prescribed for PBP, yet large-scale studies on their usage patterns are limited. This study evaluates antihistamine prescription trends and provider practices for PBP across varying burn severities from moderate to severe burns (≥20% TBSA). A treatment-pathways analysis was performed using TriNetX, a global, federated, deidentified database. Patients with burns ≥ 20% TBSA from the past 20 years (2004-2024) who developed pruritus were identified and stratified into 4 cohorts: 20%-40%, 40%-60%, 60%-80%, and ≥ 80% TBSA. The analysis evaluated trends in antihistamine prescriptions, including the number of patients treated with antihistamines, types prescribed, and median times to treatment initiation, duration, and therapy switching. The total sample included 2754 patients (20%-40% TBSA, n = 1712; 40%-60%, n = 613; 60%-80%, n = 253; ≥80%, n = 176). Over 70% received antihistamines, with hydroxyzine as the most common first-line therapy, followed by diphenhydramine. Across all cohorts, the average of the median times for initiation, therapy duration, and time before switching was 16.75 days, 90.25 days, and 27.75 days, respectively. Significant variations in the timing of therapy initiation suggest a gap in consistent symptom management during critical recovery periods, potentially affecting patient comfort and overall outcomes. These findings underscore the importance of vigilant postburn assessment, stepwise escalation based on response, and complementary strategies to optimize PBP management. Frequent switching and prolonged durations suggest a need for more effective and tailored therapeutic approaches to improve recovery outcomes for patients with burn injuries.